Skip to main content
ConductScienceScienceDex

Toni Choueiri

NIH Rank #2224
Unclaimed recordClaim profile
  • Program Leader
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 10412700Search this ID in NIH RePORTER
ORCID iD
https://orcid.org/0000-0002-9201-3217Verified identifier for this researcher
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$2.4M
Full award amounts, FY2026
Award Records
3
Records listing this PI
Award-Linked Rank
#2,224
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Toni Choueiri. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

NCI

National Cancer Institute

$16.3M

4 awards · administering

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Toni Choueiri as a PI. Multi-PI records show the full award amount for context.

  • 5P30CA006516-61P30
    Dana-Farber/Harvard Cancer Center
    Dana-Farber Cancer Institute
    $12.8M
    award amount
  • 4R01CA293091-03R01
    Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
    Dana-Farber Cancer Institute
    $2.1M
    award amount
  • 1R01CA308071-01R01
    Optimizing neoadjuvant/adjuvant anti-PD-1 therapy for localized Renal Cell Carcinoma
    Brigham and Women's Hospital
    $740K
    award amount
  • 5R01CA266424-05R01
    Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
    Dana-Farber Cancer Institute
    $713K
    award amount

Award organizations

Organizations that administered FY2026 awards listing Toni Choueiri as a PI.

Dana-Farber Cancer Institute
MA
$15.6M
3 grants
Brigham and Women's Hospital
MA
$740K
1 grant

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Dana-Farber Cancer Institute
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6004
  5. 2025
    $2M Cumulative Funding
  6. 2025
    Entered Top 25% Nationally
    Ranked #4938
  7. 2025
    Multi-Institutional Research
    Awards at 2 institutions
  8. 2025
    R01 Grant Holder
  9. 2025
    Program/Center Grant Leader
  10. 2026
    $5M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Toni Choueiri.

A. Heather Eliassen
Dana-Farber Cancer Institute
3
shared awards
Alexander Gusev
Dana-Farber Cancer Institute
3
shared awards
Andrew A Lane
Dana-Farber Cancer Institute
3
shared awards
Benjamin Levine Ebert
Dana-Farber Cancer Institute
3
shared awards
Brian Matthew Wolpin
Dana-Farber Cancer Institute
3
shared awards
Deborah J Goff
Dana-Farber Cancer Institute
3
shared awards
Eliezer M Van Allen
Dana-Farber Cancer Institute
3
shared awards
Frank S Hodi
Dana-Farber Cancer Institute
3
shared awards
Franziska Michor
Dana-Farber Cancer Institute
3
shared awards
Geoffrey I. Shapiro
Dana-Farber Cancer Institute
3
shared awards

Explore further

Find collaborators for Toni Choueiri

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →